← Back to Search

Genetic Testing for Alcohol Flushing (AIAC Trial)

N/A
Waitlist Available
Led By Kevin Chang, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult age over 18
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 1 month, 3 month

Summary

This trial aims to increase awareness about alcohol flushing and its health risks. The main goal is to determine if educating people about the health risks of alcohol flushing and providing personalized genetic information will change how much alcohol

Who is the study for?
This trial is open to adults over the age of 18 who are native English speakers. There are no specific exclusion criteria, so it's quite inclusive for those interested in learning about alcohol flushing and its health risks.
What is being tested?
The study focuses on whether educating people about the dangers of alcohol flushing and providing them with their personal ALDH2 genotype information can influence their drinking habits.
What are the potential side effects?
Since this trial involves genotyping and education without direct medical interventions, there aren't any traditional side effects associated with participation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am over 18 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 month, 3 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 1 month, 3 month for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Alcohol Consumption Habits 1
Alcohol Consumption Habits 2
Alcohol Consumption Habits 3
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Genotype RevealedExperimental Treatment1 Intervention
Subjects with ALDH2 mutation will be notified of positive genotype results after testing completed.
Group II: Gentoype Not-RevealedPlacebo Group1 Intervention
Subjects with ALDH2 mutation will not be notified of positive genotype results until after study completed.

Find a Location

Who is running the clinical trial?

Stanford Center for Asian Health Research and EducationUNKNOWN
Stanford UniversityLead Sponsor
2,474 Previous Clinical Trials
17,501,840 Total Patients Enrolled
Kevin Chang, MDPrincipal InvestigatorStanford University
~12 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top